The 3.2 million-square-foot distribution center for Amazon would rise nearly five stories at the site, if the plans are ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Again, it's going to be progressive learning, building ... sharing with Regeneron and the end of the reimbursement for R&D there, which is coming at the end of '26, beginning of '27.

Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...

N.; new building; same AimPoint LLC; 67 Annandale Drive; new single-family residence; Rhett Construction AimPoint LLC; 77 Annandale Drive; new single-family residence; Rhett Construction ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Collectively, they were anticipating Regeneron would book $3.76 billion in revenue, filtering down to adjusted net income of $11.27 per share. Sales of its leading product, retina disorder ...

Regeneron Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for linvoseltamab, an investigational treatment for adult patients with ...

Join Lee Rennick from the CIO100 with Bob McCowan, SVP & CIO, Regeneron as he discusses the award-winning Centralized Data Project, tech modernization, cloud native approach to data and leadership.